104.25 +0.24 (0.23%)
After hours: 5:47PM EDT
|Bid||102.00 x 400|
|Ask||105.10 x 100|
|Day's Range||103.37 - 108.05|
|52 Week Range||17.33 - 111.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||91.57|
Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) generates revenues from collaboration agreements through which it receives product sales revenues, royalties, license fees, milestone payments, and contract research payments. In fiscal 2017, Nektar Therapeutics generated total revenues of $307.7 million compared with $165.4 million in fiscal 2016.
Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) is a biopharmaceutical company with investigational drug candidates for the treatment of cancer, autoimmune disease, and chronic pain. Of the nine analysts covering Nektar Therapeutics in March 2018, four of them have given the stock a “strong buy” rating.
Take-Two Interactive Software Inc., SVB Financial Group and Nektar Therapeutics are joining the S&P 500 index, according to S&P Dow Jones Indices.
NEW YORK , March 9, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents ...
SAN FRANCISCO , March 7, 2018 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Scientific Officer, Jonathan Zalevsky , Ph.D., is scheduled to present at the upcoming ...
NEW YORK, NY / ACCESSWIRE / March 5, 2018 / Shares of Nektar Therapeutics and Zosano Pharma both blew up in Friday trading. Nektar saw big gains after reporting better than expected fourth quarter results ...
Nektar (NKTR) reports narrower-than-expected loss in Q4. Revenues substantially rise year over year owing to massive increase in license and collaboration fees.
SAN FRANCISCO , March 1, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2017. Cash and investments in marketable ...
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Nektar Therapeutics (NASDAQ: NKTR ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 5:00 PM Eastern Time. ...
Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Shares of Nektar were soaring on Wednesday despite any catalyst. It was earlier in the month that the company announced a huge agreement with Bristol-Myers. ...